Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-ABL tyrosine kinase inhibitors. Treatment options for newly diagnosed chronic phase disease are dominated by TKIs, including first-to-market Gleevec (Novartis), Sprycel (Bristol-Myers Squibb), and Tasigna (Novartis); treatment options for patients who are resistant or intolerant to prior therapy (and in patients with accelerated and/or blast phase disease) include Bosulif (Pfizer), Iclusig (Ariad), and Synribo (Teva).

Questions Answered:

  • What percentage of drug-treated, newly diagnosed, chronic phase chronic myeloid leukemia patients are prescribed BCR-ABL tyrosine kinase inhibitors as first-line and second-line treatment by surveyed physicians?
  • What are the key drivers and obstacles determining current prescribing patterns in the chronic myeloid leukemia treatment armamentarium?
  • How the entry of generic Gleveec has affected the treatment preference of hematologists?
  • What are surveyed physicians’ perceptions of the intended duration of tyrosine kinase inhibitor treatment for chronic myeloid leukemia versus their actual clinical practice? To what extent are their patients compliant?

Product Description:

Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.

Table of contents

  • Chronic Myeloid Leukemia - Current Treatment - Detailed, Expanded Analysis (US)
    • Key Updates
      • December 2017
    • Introduction to Current Treatment for CML
      • Key Findings
      • Summary Figures
        • Weighted Patient Share of Drug Therapies for Newly Diagnosed Chronic Phase CML Regardless of Risk Category
        • Patient Share of Drug Therapies for Previously Drug-Treated Chronic Phase CML Patients
        • Permanent Discontinuation of TKI Therapy Among Long-Term Responders in Newly Diagnosed Chronic Phase CML
      • Introduction to Current Treatment and Medical Practice for CML
      • Drugs Included in this Study of Current Treatment of CML
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Less Than 30% of Newly Diagnosed Chronic Phase CML Patients Are Deemed at High Risk
        • Risk Stratification in Newly Diagnosed CML Patients
        • Physician-Reported Rate of T315I Mutation Among CML Patients Who Undergo Mutation Analysis
      • Physician Treatment Practices for Newly Diagnosed Patients
        • Well-Established TKIs Dominate CML Treatment Armamentarium
        • At Least 70% of Newly Diagnosed CML Patients Receive Antineoplastic Drug Therapy Outside of Clinical Trials
        • Drug-Treatment Rates for Newly Diagnosed CML Patients
        • Allogeneic Stem Cell Transplant Sees Higher Use for Accelerated Phase CML
        • Percentage of Newly Diagnosed CML Patients Receiving Allogeneic Stem Cell Transplant
        • Imatinib Is the Patient-Share Leader for Newly Diagnosed Chronic Phase CML
        • Patient Share of Drug Therapies for Newly Diagnosed Chronic Phase CML
        • Patient Share of Drug Therapies for Newly Diagnosed Advanced Phase CML
        • Imatinib has the Highest Average Treatment Duration for Newly Diagnosed Chronic Phase CML Patients
        • Average Treatment Duration in Newly Diagnosed Chronic Phase CML Patients
        • About a Fifth of Long-Term Responders Permanently Discontinue TKI Therapy
        • Drug Compliance Rates in Newly Diagnosed Chronic Phase CML Patients
        • Permanent Discontinuation of TKI Therapy Among Long-Term Responders in Newly Diagnosed Chronic Phase CML
        • Early Drug-Discontinuation Rates in Newly Diagnosed Chronic Phase CML Patients
      • Physician Treatment Practices for Recurrent Patients
        • The Choice of Agent Becomes More Fragmented in Later Lines of Chronic Phase CML Treatment
        • The Majority of Previously Treated Chronic Phase CML Patients Receive Antineoplastic Treatment Outside of Clinical Trials
        • Drug-Treatment Rates for Previously Treated Chronic Phase CML Patients
        • Bosulif and Iclusig Capture More Use as Third-Line Therapies in Chronic Phase CML Patients
        • Patient Share of Drug Therapies for Previously Treated Chronic Phase CML
        • Treatment Durations Fall in Later Lines of Therapy for Chronic Phase CML
        • Intended vs. Actual Treatment Duration in Second-Line Chronic Phase CML
        • Intended vs. Actual Treatment Duration for Synribo in Third-Line Chronic Phase CML
        • Compliance Rates Are Similar Between Key Agents Prescribed for Second-Line Chronic Phase CML
        • Drug Compliance Rates in Second-Line Treatment for Chronic Phase CML
        • Drug Compliance Rate of Synribo in Third-Line Therapy for Chronic Phase CML
        • Over 40% of Drug-Treated, Second-Line Chronic Phase CML Patients Are Eligible for Further Therapy
        • Disease Progression in Second-line Chronic Phase CML
      • Sequencing of Treatment
        • Only a Minority of Respondents Would Prescribe Bosulif After Resistance or Intolerance to First-Line TKI Therapy
        • Sequencing of Therapies in Chronic Phase CML
        • Choice of Second-Line Therapy for Chronic Phase CML Patients Intolerant to First-Line TKI Treatment
        • Choice of Second-Line Therapy for Chronic Phase CML Patients Resistant to First-Line TKI Treatment
        • Statement Agreement on Select Market Issues in CML
      • Recent and Anticipated Changes in Treatment Practices
        • Nearly Half of Respondents Reported No Change in Use of Branded Gleevec After Entry of Generic Imatinib
        • Change in Prescription Pattern Due to Availability of Generic Imatinib in First-Line Chronic Phase CML
        • Statement Agreement on Select Market Issues in CML
    • Physician Insight on Medical Practice
      • Key Findings
      • Factors Influencing Treatment Practice
        • Efficacy and Treatment Guideline Recommendations Are Key Drivers of Choice of First-Line Therapy for Chronic Phase CML
        • Drivers of Imatinib Use in Newly Diagnosed Chronic Phase CML
        • Drivers of Sprycel Use in Newly Diagnosed Chronic Phase CML
        • Drivers of Tasigna Use in Newly Diagnosed Chronic Phase CML
        • High Patient Copays/Out-of-Pocket Costs Are a Barrier to Patient Compliance with Sprycel and Tasigna
        • Factors Discouraging Patient Compliance to Imatinib in Newly Diagnosed Chronic Phase CML
        • Factors Discouraging Patient Compliance to Imatinib in Newly Diagnosed Chronic Phase CML
        • Factors Discouraging Patient Compliance to Tasigna in Newly Diagnosed Chronic Phase CML
        • Primary and Secondary Resistance to Therapy and Safety Are Among the Top Reasons for Early TKI Discontinuation
        • Rationale for Early Discontinuation of Imatinib in Newly Diagnosed Chronic Phase CML Patients
        • Rationale for Early Discontinuation of Sprycel in Newly Diagnosed Chronic Phase CML Patients
        • Rationale for Early Discontinuation of Tasigna in Newly Diagnosed Chronic Phase CML Patients
    • Methodology
      • Primary Market Research Methodology
      • Physician Average Time in Practice Postresidency
      • Average Number of CML Patients Treated per Month
      • Percentage of Respondents Treating Patients with Accelerated or Blast Phase CML
      • Agents Prescribed by Hematologist-Oncologists for CML
      • Respondent Demographics: Region
      • Respondent Demographics: State
      • Respondent Practice Settings
      • Average Time in Clinical Practice
    • Appendix
      • Primary Market Research
        • Bibliography
        • Key Abbreviations

Author(s): Swati Tyagi, M.Sc, MBA

Swati Tyagi, is a Senior Business Insight Analyst in the oncology team at the Decision Resources Group.

She comes with 8 years of work experience from the life sciences market research industry. She has in-depth expertise in competitive intelligence, secondary and primary research, and strategic projects across multiple oncology indications. Prior to joining the company, she was a delivery manager in a market research organization, where she was handling a major client engagement account and a dedicated team of senior and business analysts working for the specialty medicine brands of the client. She holds an M.Sc in biotechnology and MBA from Amity University, India.